|By Marketwired .||
|September 27, 2013 05:44 AM EDT||
WASHINGTON, DC -- (Marketwired) -- 09/27/13 -- Cerora President and CEO, Adam J. Simon presented the company's patent pending "Near the Playing Field" wireless mobile brain injury detection device and software Wednesday to industry leaders, business development professionals, potential investors, policy-makers, members of the media, and legal experts attending the annual AdvaMed conference.
AdvaMed 2013: The MedTech Conference was held September 23-25 in Washington D.C. AdvaMed 2013 brought together representatives from approximately 1,000 global medical device and diagnostic companies.
Simon addressed the audience highlighting the importance of providing reasonably priced, accurate, accessible, and easy to use solutions for the assessment and evaluation of people with suspected brain injury and other neurological and neuropsychiatric conditions. Cerora's MindReader device allows healthcare practitioners, including certified athletic trainers, nurses, and other affiliated health care practitioners to quickly collect data on site which is then transmitted wirelessly using Cerora software for rapid, remote evaluation by physicians and clinical psychologists.
Simon stressed "Cerora's value proposition is the ability to move the urgent follow-up to a suspected brain injury from a highly subjective clinical impression to rapid and objective biosensor-based measurements in an accurate, accessible format that is easy to use by field clinicians." Simon presented company concussion data discussed at an international Traumatic Brain Injury conference earlier this year.
Technology Also Shows Promise in Diagnosis of Alzheimer's / Other Neurologic Conditions
Simon also discussed Cerora's recently published peer reviewed paper (June 2013) in Annals of Biomedical Engineering (1) reporting results of the company's pilot Alzheimer's disease diagnostic study which was conducted in 2011 at Palm Drive Hospital (Sebastopol, CA) in collaboration with Villanova University.
Commenting on the diverse applications for Cerora's technology, David M Devilbiss, PhD, Cerora's Head of Research and Development stated that "Cerora's technology platform of neurophysiological and neuropsychological test batteries has been designed to be portable, user friendly, and sensitive to changes in brain function. The approach has broad applicability ranging from detecting acute changes such as mild traumatic brain injury (concussion) to developmental disorders such as Autism to neurological diseases including Alzheimer's disease." Villanova University Professor and Chair of the Center for Non-linear Dynamics, Hashem Ashrafiuon, and his team were instrumental in developing the signal processing algorithms and software used in the study.
This pilot clinical study was led by Allan L. Bernstein, MD, board certified neurologist and clinical faculty member at the University of California, San Francisco, accompanied by his clinical research coordinator Terry Hess. The study examined a small sample of patients with mild to moderate dementia of the Alzheimer's type compared to healthy age-matched control subjects.
Dr. Bernstein expressed, "the non-invasive MindReader technology made it easy to gather data from patients in an outpatient setting and was readily accepted by dementia participants. It makes it easier to develop a biomarker for patients with varying degrees of cognitive impairment." Dr. Bernstein added that the preliminary data suggests that more detailed studies should be initiated on larger populations including other potential pathologies of cognitive impairment.
About Traumatic Brain Injury (TBI)
TBI often referred to as concussion is due to mechanical forces causing brain injury. It affects toddlers, athletes, traffic accident victims, military warfighters, and seniors to name a few. Incidence estimates range from 1.7 million to 3.8 million per year in the United States. The problem today is diagnosing a mild closed head injury is very subjective. Furthermore, management of the return to activity decision is a real challenge.
About Alzheimer's disease (AD)
Alzheimer's disease (AD) is a chronic neurodegenerative disorder affecting millions of people worldwide. It is the number one form of dementia in the world. Dementia, a loss of mental function affecting memory, cognition, speech etc., has a variety of causes and is believed to reflect underlying dysfunction of brain cells. The risk of being afflicted with AD increases with age, with one in nine people over the age of 65 having the disease. Please refer to the Alzheimer's Association Facts and Figures (2).
Cerora, Inc. is a healthcare information technology company focused on providing accessible and affordable neuro-diagnostic information with a particular focus on concussion (mTBI). For more information about Cerora, please refer to the company's website www.cerora.com
(1) Ghorbanian, P. et al. Identification of Resting and Active State EEG Features of Alzheimer's Disease using Discrete Wavelet Transform. Ann Biomed Eng 41(6):1243-1257, June 2013.
(2) Alzheimer's Association, 2013. 2013 Alzheimer's Disease Facts and Figures, Alzheimer's & Dementia 9(2). To download the report, see: www.alz.org/downloads/facts_figures_2013.pdf.
+1 (510) 517-5982